Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + S-488210/S-488211 in Non-muscle Invasive Bladder Cancer
NCT04106115Phase 2Recruiting
- Sponsor
- University College London
- Start
- Mar 2022
- Primary completion
- Mar 2027
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, S-488210/S-488211 in Non-muscle-invasive bladder cancer (NMIBC), sponsored by University College London. Started Mar 2022; status: recruiting.
02
Drugs
durvalumabS-488210/S-488211
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04106115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106115.